Business Wire

Synteract Bolsters Its Oncology, Neuro Degenerative and Rare Disease Centers of Development with Two New Executives

Share

Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, continues its commitment to specialized Centers of Development as it adds two new executives to the team. Christopher Heckman, RN, BSN, joins as the vice president for oncology development and will build the company’s Center of Development in Oncology while Art Wamil, M.D., Ph.D., joins as senior medical director and lead neurologist to further strengthen its Neuro Degenerative and Rare Disease Centers of Development. Since focusing its expertise in five Centers of Development in 2018, Synteract has seen increasing opportunities in its biopharma business, especially in oncology and neuro degenerative areas, coming from both rare disease and non-rare indications.

With 23 years of clinical research experience, Christopher Heckman is an accomplished leader with management, clinical and business development experience. He possesses a broad experience base across the drug development lifecycle, with both strategic and operational lines of responsibility, with hands-on engagement in all development phases as well as global registration experience. Previously, he has held leadership positions for portfolio management with both large and small CROs and managed an oncology product to regulatory approval for a major pharmaceutical company.

Dr. Wamil is a neurologist/electrophysiologist with more than 20 years of scientific and medical experience in the healthcare and biotech/pharmaceutical industries, primarily in neurology, neuroscience/CNS, and diagnostic medicine fields, working with both adults and children. He has co-authored more than 30 scientific papers and over 70 scientific abstracts, posters and presentations, and is an active member of AAN, AES, MDS, AHA/ASA, and AMA.

CEO Steve Powell says, “We are delighted to add these experienced leaders to the organization as they both offer breadth and depth of knowledge in their respective therapeutic areas and a keen understanding of what is needed to move studies through the complex clinical development process. Their years of experience and expansive scientific and medical capabilities will add to our already strong teams. I am confident they will be valuable additions in informing the best strategies for the trials we undertake on our clients’ behalf.”

Dr. Wamil received his M.D. and Ph.D. from Medical University of Lublin (MUL) in Poland and completed his internships, residencies and fellowships at MUL, Vanderbilt University, and Northwestern University/Children’s Memorial Hospital. He trained in electrophysiology/epilepsy and previously served on the faculty in Neurology and Anesthesiology at Vanderbilt University Medical Center for over 10 years.

Mr. Heckman received his Bachelor of Science in Nursing and Organic Chemistry from Misericordia University and completed coursework for an MBA in Finance at the Iacocca Institute at Lehigh University, both in Pennsylvania.

About Synteract

Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. With 800 employees across 21 countries, Synteract supports biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries. It has contributed to more than 240 product approvals. Synteract offers a notable depth of therapeutic expertise in oncology, dermatology, neuro degenerative, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter.

Contact information

Beth Walsh
beth@clearpointagency.com
760-230-2424

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

flatex AG: Record Half-Year and Three-Digit Growth Rates2.7.2020 07:30:00 CESTPress release

flatex AG (WKN: FTG111, ISIN: DE000FTG111111, Ticker: FTK.GR) presented record figures for the first half of the year. With pro-forma 37.6 million transactions, flatex and DEGIRO had processed significantly more transactions than in the entire year 2019. At the same time, flatex and DEGIRO gained approximately 290,000 new customers in only 6 months, which corresponds almost to a quadrupling of the number of new customers compared to the same period of the previous year. "We closed the first half of the year with an absolute record, both operationally and financially. We are very proud of this development. We knew that volatility has a positive impact on our transaction figures. But much more important is the absolute growth in new clients, which will make a sustainable contribution to the company's future success. Our original guidance was pro-forma 35 million transactions and one million customers for the entire year 2020. As promised, we achieved this goal much earlier," said Frank N

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX ® ) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer2.7.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials. CONTACT-01 is evaluating the safety and efficacy of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an immune checkpoint inhibitor and platinum-containing chemotherapy. CONTACT-02 is evaluating the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (CRPC) who have previously been treated with one NHT. “There is a growing body of preclinical and clinical evidence that cabozantinib may positively impact treatment when paired with immunotherapy,” said Dr. Howard Mayer, Executive Vice President and Hea

Sofinnova Partners Announces Two First Investments from its MD Start III Medtech Acceleration Fund2.7.2020 07:00:00 CESTPress release

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the second investment from its MD Start III Fund, a medtech accelerator that actively works with clinicians and entrepreneurs to develop disruptive medical devices. In May 2019, the fund raised €48 million from key institutional investors and has made two seed investments so far: MastOR and Gradient Denervation Technologies. The most recent investment is in MastOR, a French company leveraging its core expertise in surgical robotics to develop enhanced laparoscopic devices to improve the precision and ergonomics of minimally-invasive surgery. The company was founded in 2019 by a renowned pioneer in laparoscopic surgery, Professor Brice Gayet of the Paris-based Institut Mutualiste Montsouris, and entrepreneur, Pierre Campredon. “The Sofinnova MD Start team is known for its active, hands-on approach to company building,” said Prof. Gayet. “Their strategic and operati

European Commission approves extended Invokana ® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes seen in CREDENCE study2.7.2020 01:01:00 CESTPress release

STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY Mundipharma today announces that the European Commission (EC) has approved the extension of the indication of Invokana® (canagliflozin) to include important renal outcome data from the landmark Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial.1 Canagliflozin is now the only sodium glucose co-transporter 2 inhibitor (SGLT2i) approved in Europe with an extended indication to treat diabetic kidney disease (DKD) in type 2 diabetes (T2DM) patients. For the first time in Europe, T2DM patients with an estimated glomerular filtration rate (eGFR) between 60 and 45 mL/min/1.73m2 can now initiate treatment with canagliflozin 100mg. In addition, T2DM patients with albuminuria and an eGFR ≥30 mL/min/1.73m2 can now start treatment with canagliflozin 100mg and continue until dialysis or renal transplantation.4 “We are delighted with this extended indication granted by the E

Inaugural Virtual Edition of LiveWorx Digital Transformation Event Draws Thousands1.7.2020 22:00:00 CESTPress release

For the first time in the event’s decade-long history, the annual https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.liveworx.com%2F&esheet=52244398&newsitemid=20200701005892&lan=en-US&anchor=LiveWorx%26%23174%3B+digital+transformation+event&index=1&md5=47f7c44c1f95c008ad805bccddf0d2a3 LiveWorx® digital transformation event took place online, uniting tens of thousands of industry leaders across the world. Chaired by presenting sponsor,PTC (NASDAQ: PTC), the one-day event featured more than 120 sessions spanning topics ranging from Augmented Reality (AR), Artificial Intelligence (AI), 5G, Robotics, Software as a Service (SaaS), Industrial Internet of Things (IIoT), Product Lifecycle Management (PLM), and Computer-Aided Design (CAD), and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005892/en/ “This year’s virtual event brought to life the magic, excitement, and drive for transformative change th

MHPS’ T-Point 2 Enters Commercial Operation with the World’s Largest and Most Efficient 60 Hz Gas Turbine1.7.2020 21:24:00 CESTPress release

Mitsubishi Hitachi Power Systems, Ltd. (MHPS) announced today that its T-Point 2 combined cycle power plant validation facility entered full commercial operation with an enhanced JAC gas turbine that sets the record for output and efficiency. The T-Point 2 plant was commissioned in March at Takasago Works in Hyogo Prefecture, Japan, to replace MHPS’ original T-Point plant and to continue MHPS’ approach — which is unlike any other manufacturer’s — to advance the limits of technology while minimizing risk to its customers. To do this, MHPS validates its new gas turbine technologies and digital solutions under long-term grid-connected operation for a minimum of 8,000 operating hours, which is equivalent to nearly one year of normal operation and is a key insurance industry criterion for fleet reliability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005896/en/ Mitsubishi Hitachi Power Systems’ T-Point 2 combined cycle p